Abstract：In recent years, a large number of pre-clinical and clinical investigations have indicated that stereotactic body radiation therapy (SBRT) can not only kill cancer cells directly,but also induce the immunogenic death of cancer cells through releasing numerous tumor-associated antigens and damage-associated molecular patterns to form in situ tumor vaccine. CD8(+) T cells in lymph nodes are cross-sensitized by activated antigen-presenting cells. SBRT initiates local and systemic anti-tumor immune response. Moreover, SBRT can induce the abscopal effect if combined with immunotherapy. In addition, SBRT improves the microenvironment for tumor immunosuppression and enhances the sensitivity of tumors to immunotherapy. This article reviews the research advances in the synergistic mechanisms for combination therapy with SBRT and immunotherapy.
Li Jiaqi,Wang Hao,Yang Ruijie. Research advances in mechanisms for combination therapy with stereotactic body radiation therapy and immunotherapy[J]. Chinese Journal of Radiation Oncology, 2017, 26(12): 1465-1469.
[1] Jaffray DA.Image-guided radiotherapy:from current concept to future perspectives[J].Nat Rev Clin Oncol,2012,9(12):688-699.DOI:10.1038/nrclinonc. [2] Obeid M,Panaretakis T,Joza N,et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis[J].Cell Death Differ,2007,14(10):1848-1850.DOI:10.1038/sj.cdd.4402201. [3] Reynders K,Illidge T,Siva S,et al. The abscopal effect of local radiotherapy:using immunotherapy to make a rare event clinically relevant[J].Cancer Treat Rev,2015,41(6):503-510.DOI:10.1016/j.ctrv.2015.03.011. [4] Brown J,Carlson D,Brenner D,et al. The tumor radiobiology of SRS and SBRT:are more than the 5 Rs involved?[J].Int J Radiat Oncol Biol Phys,2014,88(2):254-262.DOI:10.1016/j.ijrobp. [5] Dunn G,Old LJ,Schreiber RD,et al. The three Es of cancer immunoediting[J].Annu Rev Immunol,2004,22:329-360. [6] Chen Z,Moyana T,Saxena A,et al. Efficient antitumor immunity derived from maturation of dendritic cells that had phagocytosed apoptotic/necrotic tumor cells[J].Int J Cancer,2001,93(4):539-548. [7] Gameiro S,Jammeh ML,Wattenberg MM,et al. Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure,resulting in enhanced T-cell killing[J].Oncotarget,2014,5(2):403416.DOI:10.18632/oncotarget.1719. [8] Lotze MT,Zeh HJ,Rubartelli A,et al. The grateful dead:damage-associated molecular pattern molecules and reduction/oxidation regulate immunity[J].Immunol Rev,2007,220:60-81.DOI:10.1111/j.1600-065X.2007.00579.x. [9] Apetoh L,Ghiringhelli F,Tesniere A,et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy[J].Immunol Rev.2007;220:47-59.DOI:10.1111/j.1600-065X.2007.00573.x. [10] Perregaux DG,McNiff P,Laliberte R,et al. ATP acts as an agonist to promote stimulus-induced secretion of IL-1 beta and IL-18 in human blood[J].J Immunol,2000,165(8):4615-4623. [11] Panaretakis T,Kepp O,Brockmeier U,et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death[J].EMBO J.2009;28(5):578-590.DOI:10.1038/emboj [12] Pawaria S,Binder RJ.CD91-dependentprogramming of T-helper cell responses following heat shock protein immunization[J].Nat Commun,2011,2:521.DOI:10.1038/ncomms1524. [13] Woo SR,Fuertes MB,Corrales L,et al. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors[J].Immunity,2014,41(5),830-842.DOI:10.1016/j.immuni.2014.10.017. [14] Surace L,Lysenko V,Fontana AO,et al. Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response[J].Immunity,2015,42(4):767-777.DOI:10.1016/j.immuni.2015.03.009. [15] Barker H,Paget J,Khan A,et al. The tumor microenvironment after radiotherapy:mechanisms of resistance and recurrence[J].Nat Rev Cancer,2015,15(7):409-425.DOI:10.1038/nrc3958. [16] Park HJ,Griffin RJ,Hui S,et al. Radiation-induced vascular damage in tumors:Implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)[J].Radiat Res,2012;177(3):311-327. [17] Matsumura S,Wang B,Kawashima N,et al. Radiation-induced CXCL16 releaseby breast cancer cells attracts effector T cells[J].J Immunol,2008,181(5):3099-3107. [18] Cao M,Cabrera R,Xu Y,et al. Different radiosensitivity of CD4(+) CD25(+) regulatory T cells and effector T cells to low dose gamma irradiation in vitro[J].Int J Radiat Biol,2011,87(1):71-80.DOI:10.3109/09553002.2010.518208. [19] Demaria S,Coleman C,Formenti S,et al. Radiotherapy:Changing the Game in Immunotherapy[J].trends in cancer,2016,2(6):286-294.DOI:10.1016/j.trecan.2016.05.002. [20] Cronstein BN.Adenosine,an endogenous anti-inflammatory agent[J].J Appl Physiol,1994,76(1):5-13. [21] Chen W,Jin W,Hardegen N,et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25-regulatory T cells by TGF-beta induction of transcription factor Foxp3[J].J Exp Med,2003,198(12):1875-1886.DOI:10.1084/jem.20030152. [22] Herrera FG,Bourhis J,Coukos G,et al. Radiotherapy combination opportunities leveraging immunity for the next oncology practice[J].CA Cancer J Clin,2016,0(0):1-21.DOI:10.3322/caac.21358. [23] Abuodeh Y,Venkat P,Kim S,et al. Systematic review of case reports on the abscopal effect[J].Current Problems in Cancer,2016,40(1):25-37.DOI:10.1016/j.currproblcancer.2015.10.001 [24] Melief CJ,Van Hall T,Arens R,et al. Therapeutic cancer vaccines[J].J Clin Invest,2015,125(9):3401-3412.DOI:10.1172/JCI80009. [25] Wei S,Egenti M,Teitz S,et al. Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice[J].J Immunother,2013,36(2):124-132.DOI:10.1097/CJI.0b013e31828298e6. [26] Pardoll DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer,2012,12(4):252-264.DOI:10.1038/nrc3239. [27] Robert L,Tsoi J,Wang X,et al. CTLA4 blockade broadens the peripheral T-cell receptor repertoire[J].Clin Cancer Res,2014,20(9):2424-2432.DOI:10.1158/1078-0432.CCR-13-2648. [28] Yoshimoto Y,Suzuki Y,Mimura K,et al. Radiotherapy-induced anti-tumor immunity contributes to the therapeutic efficacy of irradiation and can be augmented by CTLA-4 blockade in a mouse model[J].PLoS One,2014,9(3):e92572.DOI:10.1371/journal.pone.0092572.eCollection2014. [29] Iwai Y,Ishida M,Tanaka Y,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade[J].Proc Natl Acad Sci U S A,2002,99(19):12293-12297.DOI:10.1073/pnas.192461099. [30] Dovedi S,Adlard A,Lipowska-Bhalla G,et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade[J].Cancer Res,2014,74(19):5458-5468.DOI:10.1158/0008-5472.CAN-14-1258. [31] Twyman-Saint VC,Rech AJ,Maity A,et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer[J].Nature,2015,520(7547):373-377.DOI:10.1038/nature14292. [32] Baksh K,Weber J.Immune checkpoint protein inhibition for cancer:preclinical justification for CTLA-4 and PD-1 blockade and new combinations[J].Semin Oncol,2015,42(3):363-77.DOI:10.1053/j.seminoncol.2015.02.015. [33] Yasuda K,Nirei T,Tsuno N,et al. Intratumoral injection of interleukin-2 augments the local and abscopal effects of radiotherapy in murine rectal cancer[J].Cancer Sci,2011,102(7):1257-1263.DOI:10.1111/j.1349-7006.2011.01940.x. [34] Krieg AM.Antitumor applications of stimulating toll-like receptor 9 with CpG oligo deoxynucleotides[J].Curr Oncol Rep,2004,6(2):88-95. [35] Krieg AM.Therapeutic potential of Toll-like receptor 9 activation[J].Nat Rev Drug Discov,2006,5(6):471-484.DOI:10.1038/nrd2059. [36] Munn DH,Sharma MD,Baban B,et al. GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase[J].Immunity,2005,22(5):633-642.DOI:10.1016/j.immuni.2005.03.013. [37] Li M,Bolduc A,Hoda M,et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma[J].J Immunother Cancer,2014,2:21.DOI:10.1186/2051-1426-2-21. [38] Bouquet F,Pal A,Pilones KA,et al. TGF beta 1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo[J].Clin Cancer Res,2011,17(21):6754-6765.DOI:10.1158/1078-0432.CCR-11-0544. [39] Vanpouille-Box C,Diamond JM,Pilones KA,et al. TGF-β is a master regulator of radiation therapy-induced anti-tumor immunity[J].Cancer Res,2015,75(11):2232-2242.DOI:10.1158/0008-5472.CAN-14-3511. [40] Gough MJ,Crittenden MR,Sarff M,et al. Adjuvant therapy with agonistic antibodies to CD134(OX40) increases local control after surgical or radiation therapy of cancer in mice[J].J Immunother,2010,33(8):798-809.DOI:10.1097/CJI.0b013e3181ee7095. [41] Verbrugge I,Hagekyriakou J,Sharp L,et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies[J].Cancer Res,2012,72(13):3163-3174.DOI:10.1158/0008-5472.CAN-12-0210. [42] Tang C,Wang X,Soh H,et al. Combing radiation and immunotherapy:a new systemic therapy for solid tumors?[J].Cancer Immunol Res,2014,2(9):831-838.DOI:10.1158/2326.6066.CIR.14-0069. [43] Dewan M,Galloway AE,Kawashima N,et al. Fractionated but not single dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody[J].Clin Cancer Res,2009,15(17):5379-5388.DOI:10.1158/1078-0432.CCR-09-0265. [44] Filatenkov A,Baker J,Mueller AM,et al. Ablative tumor radiation can change thetumor immune cell microenvironment to induce durable complete remissions[J].Clin Cancer Res,2015,21(16):3727-3739.DOI:10.1158/1078-0432.CCR-14-2824. [45] Schaue D,Ratikan J,Iwamoto K,et al. Maximizing tumor immunity with fractionated radiation[J].Int J Radiat Oncol Biol Phys,2012,83(4):1306-1310.DOI:10.1016/j.ijrobp.2011.09.049. [46] Aryankalayil M,Makinde AY,Gameiro S,et al. Defining molecular signature of pro-immunogenic radiotherapy targets in human prostate cancer cells[J].Radiat Res,2014,182(2):139-148.DOI:10.1667/RR13731.1. [47] 马振峰,黄建茹,崔乃鹏,等.小剂量放疗介导人肾透明细胞癌786-0免疫原性表达的变化[J].中华医学杂志,2013,93(30):2385-2387.DOI:10.760/cma.j.issn.03762491.2013.30.012. Ma ZF,Huang JR,Cui NP,et al. Expressions of immunogenic molecules in low-dose radiotherapy-treated human renal clear cell carcinoma 786-0 cells[J].National Medical Journal of China,2013,93(30):2385-2387.DOI:10.3760/cma.j.issn.03762491.2013.30.012. [48] Lee JH, Elly C, Park Y,et al. Ubiquitin Ligase VHL Regulates Hypoxia-Inducible Factor-1α to Maintain Regulatory T Cell Stability and Suppressive Capacity[J].Immunity,2015,42(6):1062-1074.DOI:10.1016/j.immuni.2015.05.016. [49] Song CW,Lee YJ,Griffin R,et al. Indirect Tumor Cell Death After High-Dose Hypofractionated Irradiation:Implications for Stereotactic Body Radiation Therapy and Stereotactic Radiation Surgery[J].Int J Radiat Oncol Biol Phys,2015,93(1):166-172.DOI:10.1016/j.ijrobp.2015.05.016. [50] Young K,Cottam B,Baird J,et al. Ideal timing of immunotherapy with radiation in murine tumor models[J].Int J Radiat Oncol,2014,90(1):S58.DOI:http://dx.doi.org/10.1016/j.ijrobp.2014.05.202. [51] Chakravarty PK,Alfieri A,Thomas EK,et al. Flt3-ligand administration after radiation therapy prolongs survival in a murine model of metastatic lung cancer[J].Cancer Res,1999,59(24):6028-32. [52] Demaria S,Ng B,Devitt ML,Babb JS,Kawashima N,Liebes L,et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated[J].Int J Radiat Oncol Biol Phys,2004,58(3):862-70.DOI:10.1016/j.ijrobp.2003.09.012.
2017, Vol. 26 
